Literature DB >> 7126269

Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193).

H N Jayaram, D A Cooney, R I Glazer, R L Dion, D G Johns.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7126269     DOI: 10.1016/0006-2952(82)90071-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

Review 1.  Tiazofurin: a new antitumor agent.

Authors:  P J O'Dwyer; D D Shoemaker; H N Jayaram; D G Johns; D A Cooney; S Marsoni; L Malspeis; J Plowman; J P Davignon; R D Davis
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.

Authors:  K Pillwein; H N Jayaram; G Weber
Journal:  Blut       Date:  1988-08

3.  Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  R M Green; D J Stewart; J A Maroun
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

Authors:  J W Huggins; R K Robins; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

5.  Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy.

Authors:  N A Berger; S J Berger; D M Catino; S J Petzold; R K Robins
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Low nicotinamide mononucleotide adenylyltransferase activity in a tiazofurin-resistant cell line: effects on NAD metabolism and DNA repair.

Authors:  S Boulton; S Kyle; B W Durkacz
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.